The slow-cycling cells in the bulge of the outer root sheath may represent stem cells for the hair follicle. With each new anagen (growing) phase bulge cells would give rise to a population of transient-amplifying cells which differentiate into outer root sheath and matrix keratinocytes. The lowermost part of the telogen (resting) follicle is composed of bulge cells lying in close proximity to the dermal papilla. In the mouse the first hair follicle growth is characterized by rapid follicular neogen-esis, but the second and third growth cycles follow the normal follicular growth pattern. We have examined activity of cells in the bulge at the onset of anagen (growing phase) in the third hair cycle in Sencar mice, by treating animals at the end of the second telogen with colchicine to localize mitotic activity in the hair follicle. Mitoses were only seen in bulge cells during early anagen. This confirms that they proliferate transiently, solely at the onset of anagen and strongly supports the suggestion that bulge cells are the origin of the whole lower follicle in anagen.

Keywords:
Hair follicle, Bulge, Stem cells, Anagen
This content is only available via PDF.
© 1994 S. Karger AG, Basel
1994
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.